Oettgen H F
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
J Cancer Res Clin Oncol. 1990;116(1):116-9. doi: 10.1007/BF01612653.
Biological approaches to cancer therapy have gone through phases of early excitement and subsequent neglect and ridicule, and have now entered an era of renewed interest. Unlike Coley and his contemporaries a century ago we are using highly purified agents of impressive potency and specificity of action in our current studies. We have come a long way in dissecting their interactions in inflammation, immunity and hematopoiesis, but we have a long way to go in defining optimal conditions for their use in therapy. However one judges the promise biological agents hold for cancer therapy, it seems certain that they will be prominent subjects of future research.
癌症治疗的生物学方法经历了早期令人兴奋的阶段，随后遭到忽视和嘲笑，现在已进入一个重新受到关注的时代。与一个世纪前的科利及其同时代人不同，我们在当前的研究中使用的是效力强大、作用具有高度特异性的高度纯化制剂。在剖析它们在炎症、免疫和造血过程中的相互作用方面，我们已经取得了长足的进展，但在确定其用于治疗的最佳条件方面，我们还有很长的路要走。无论人们如何看待生物制剂对癌症治疗的前景，它们似乎肯定会成为未来研究的重要课题。
